Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pancreas

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/MPA.0000000000000379PMID 26262587PMCID PMC5891223
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 'Pathway drug cocktail': targeting Ras signaling based on structural pathways.

  2013cited by this paper
• Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.

  2012cited by this paper
• An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.

  2012cited by this paper
• KRAS above and beyond – EGFR in pancreatic cancer

  2012cited by this paper
• Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells

  2012cited by this paper
• EGF receptor is required for KRAS-induced pancreatic tumorigenesis.

  2012cited by this paper
• Inhibition of Ras for cancer treatment: the search continues.

  2011cited by this paper
• Genetic prognostic and predictive markers in colorectal cancer

  2011cited by this paper
• RAS oncogenes: weaving a tumorigenic web

  2011cited by this paper
• KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.

  2011cited by this paper
• Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

  2010cited by this paper
• PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

  2010cited by this paper
• Chemokine Receptor CXCR4 Enhances Proliferation in Pancreatic Cancer Cells Through AKT and ERK Dependent Pathways

  2010cited by this paper
• The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• Ras activity levels control the development of pancreatic diseases.

  2009cited by this paper
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Genetic prognostic and predictive markers in colorectal cancer

  2009cited by this paper
• Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer

  2009cited by this paper
• Erlotinib in the treatment of advanced pancreatic cancer

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

  2008cited by this paper
• In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• MAP kinase signalling pathways in cancer

  2007cited by this paper
• EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.

  2007cited by this paper
• Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Role of Group A p21-activated Kinases in Activation of Extracellular-regulated Kinase by Growth Factors*

  2005cited by this paper
• Assessment of HER-2 Status in Pancreatic Adenocarcinoma: Correlation of Immunohistochemistry, Quantitative Real-Time RT-PCR, and FISH With Aneuploidy and Survival

  2005cited by this paper
• Phosphorylation of Raf-1 by p21-activated Kinase 1 and Src Regulates Raf-1 Autoinhibition*

  2003cited by this paper
• Blocking oncogenic Ras signaling for cancer therapy.

  2001cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts

  1997cited by this paper
• Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma.

  1994cited by this paper
• Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness.

  1993cited by this paper

• Natural Polyphenols in Cancer Management: Promising Role, Mechanisms, and Chemistry.

  2023cites this paper
• ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1

  2022cites this paper
• Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer.

  2021cites this paper
• Integrative Epigenomic and Transcriptomic Analysis Reveals Robust Metabolic Switching in the Brain During Intermittent Fasting

  2020cites this paper
• Modelling of Protein Complexes Involved in Signalling Pathway for Non-small Cell Lung Cancer

  2020cites this paper
• State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?*

  2019cites this paper
• Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

  2019cites this paper
• Antiproliferative evaluation and supramolecular association in Mn(II) and Zn(II) bipyridine complexes: Combined experimental and theoretical studies.

  2019cites this paper
• A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas

  2019cites this paper
• Gelatin nonwovens-based epithelial morphogenesis involves a signaling axis comprising EGF-receptor, MAP kinases ERK 1/2, and β1 integrin.

  2018cites this paper
• Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.

  2017cites this paper
• B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells

  2017cites this paper
• FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer

  2017cites this paper
• Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.

  2016cites this paper
• Biomarkers and Targeted Therapy in Pancreatic Cancer

  2016cites this paper
• EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.

  2016cites this paper